Pazopanib
产品名称:Pazopanib
产品描述:
产品描述 | Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R, which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. |
靶点活性 | c-Kit:74 nM, PDGFR:84 nM, VEGFR1:10 nM, VEGFR3:47 nM, VEGFR2:30 nM |
体外活性 | 小鼠对Pazopanib**具有良好的耐受性,且每组小鼠的体重未出现差异.与低剂量组(载体或10 mg/kg Pazopanib)小鼠相比,高剂量组(30 mg/kg或100 mg/kg Pazopanib)小鼠负荷明显降低. |
体内活性 | 在包括SYO-1和HS-SY-II细胞的所有滑膜肉瘤细胞系中,Pazopanib均呈现剂量生长依赖的抑制作用。Pazopanib浓度为1μg/ml时,SYO-1和HS-SY-II细胞的增殖被抑制,浓度为5μ时被完全抑制。在VEGF诱导的HUVEC 细胞中,Pazopanib能有效抑制VEGFR2磷酸化作用(IC50:8 nM)。Pazopanib由于引起G1期阻滞从而抑制滑膜肉瘤细胞生长。和载体处理的细胞不同,经Pazopanib处理的SYO-1细胞中的Akts,GSK-3β,JNKs,p70 S6 激酶,和mTOR磷酸化作用受到抑制。浓度在20 mg/ml和22.5 mg/ml之间时,Pazopanib浓度逐渐增加,RPE细胞活性降低。 |
激酶实验 | VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated compound in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs[1]. |
细胞实验 | Pazopanib is prepared in DMSO and then diluted to final concentration in medium[1]. The effect of Pazopanib on cell proliferation is measured using 5-bromo-2-deoxyuridine (BrdU) incorporation method using commercially available kits. HUVEC is seeded in medium containing 5% fetal bovine serum (FBS) in type 1 collagen coated 96-well plates and incubated overnight at 37°C, 5% CO2. The medium is aspirated from the cells, and various concentrations of Pazopanib in serum-free medium are added to each well. After 30 min, either VEGF (10 ng/mL) or bFGF (0.3 ng/mL) is added to the wells. Cells are incubated for an additional 72 h and BrdU (10 μM) is added during the last 18 to 24 h of incubation. At the end of incubation, BrdU incorporation in cells is measured by ELISA. Data are fitted with a curve described by the equation, y=Vmax(1?(x/(K+x))), where K is equal to the IC50[1]. |
别名 | GW786034, 帕唑帕尼 |
分子量 | 437.52 |
分子式 | C21H23N7O2S |
CAS No. | 444731-52-6 |
存储
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
溶解度
Ethanol: <1 mg/mL
H2O: <1 mg/mL
DMSO: 81 mg/mL (185.1 mM)
( < 1 mg/mL refers to the product slightly soluble or insoluble )
联系我们:
邮箱:2519696869@qq.com
QQ: 2519696869
电话:18066853083
微信:18066853083
公司介绍:
西安齐岳生物科技有限公司是集化学科研和定制与一体的高科技化学公司。业务范围包括化学试剂和产品的研发、生产、销售等。涉及产品为通用试剂的分销、非通用试剂的定制与研发,涵盖生物科技、化学品、中间体和化工材料等领域。
主营产品:COF、MOF单体系列:三蝶烯衍生物、金刚烷衍生物、四苯甲烷衍生物、peg、上转换、石墨烯、光电材料、点击化学、凝集素、载玻片、蛋白质交联剂、脂质体、蛋白、多肽、氨基酸、糖化学等。